파마리서치
214450KOSDAQ의료용품 및 기타 의약 관련제품 제조업52.1 / 100
Reference Date: 2026-07-24
Company InformationBased on 2025 Annual Report
Business Overview
Parmaresearch is a biopharmaceutical company specializing in regenerative medicine, leveraging PDRN/PN technology to develop and sell pharmaceuticals, medical devices, and cosmetics. Established in 2013 with a GMP-certified factory in Gangneung and expanded with a second plant in 2019, the company's key products include Regenix, Rejuran, and Conjuuran. It plans to expand into Asian, European, and North American markets, while its subsidiary also operates a botulinum toxin business.
Number of Employees
526people
Average Salary
68.5M KRW
Score Calculation Basis
Detailed Financial Score
1.6x industry avg (risky)
4.7x industry avg (risky)
Well below industry avg
4.2x industry avg (risky)
Avg ▲43.7% (2-year basis)
Avg ▲53.4% (2-year basis)
Avg ROE 20.6% (improving, 3yr)
Detailed News Sentiment
- Positive코스피 4% 넘게 뛰어 7000선…코스닥은 5% 넘게 상승
코스피의 급등이 파마리서치를 포함한 관련 주식들에 긍정적인 영향을 미치고 있다.
- Neutral100대 기업 임원도 고령화…평균연령 54.2세, 10년 새 1.1세...
The news focuses on general leadership demographics across large corporations, lacking direct impact on Parmesis's stock performance.
- Positive파마리서치, 부산서 '2026 아트 심포지엄' 성료
파마리서치의 부산 심포지엄 성공 개최로 인해 전문 의료 전문가들의 네트워킹 강화 및 최신 트렌드 공유가 이루어져 기업 이미지 제고에 기여.
Detailed Momentum
Near 52w low (19%, downtrend)
1m +18.23% (strong rise)
Volume decreasing
Detailed Disclosure
- Neutral결산실적공시예고2026-07-14
- Neutral기업설명회(IR)개최2026-06-26
